76results about "Peptide sources" patented technology

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

Compositions and methods are provided for treating diseases associated with abnormal glycosylation of cell surface molecules and the expression of tumor-associated carbohydrate antigen (TACA). Also provided are a bispecific fusion protein and a chimeric antigen receptor (CAR) specific for a tumor-associated carbohydrate antigen (TACA-CAR), a vector encoding the TACA-bispecific fusion protein and the TACA-CAR, and a recombinant cell comprising the TACA-bispecific fusion protein and the TACA-CAR.

This invention provides artificial nucleic acid molecules that enhance the efficacy of therapeutic nucleic acids. [Solution] The present invention provides an artificial nucleic acid molecule comprising a novel combination of 5' and 3' untranslated region (UTR) factors. The nucleic acid molecule of the present invention is preferably characterized by increased expression efficiency of a coding region operably linked to the UTR factors. The artificial nucleic acid can be used for the treatment or prevention of various diseases. The present invention further provides (pharmaceutical) compositions, vaccines, and kits comprising the artificial nucleic acid molecule. Furthermore, an in vitro method for preparing the artificial nucleic acid molecule of the present invention is provided.

This invention provides compounds and methods for regulating dmpk expression and treating diseases and conditions in which dmpk plays an active role. [Solution] A transcription modulator molecule is provided having a first end, a second end, and an oligomeric skeleton, wherein a) the first end includes a DNA-binding portion that can non-covalently bind to a nucleotide repeat sequence GAA, b) the second end includes a protein-binding portion that binds to a regulatory molecule that modulates the expression of a gene containing the nucleotide repeat sequence GAA, and c) the oligomeric skeleton includes a linker between the first end and the second end.

The present disclosure provides isolated peptides derived from hepatitis B virus (HBV), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding these peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and uses thereof for the treatment or prevention of HBV infection and / or diseases induced by HBV. The present disclosure also provides binding moiety structures that bind to the peptides or peptide-based molecules disclosed herein, and uses thereof for the treatment or prevention of HBV infection and / or diseases induced by HBV. The present disclosure further provides methods and systems for identifying immunogenic virus-derived peptides.

To provide not only improved delivery systems, but also means for producing such systems which find compatibility with molecules (payloads) having a range of sizes and molecular properties.SOLUTION: The present invention provides use of a Photorhabdus Virulence Cassettes (PVC) effector leader sequence, for packaging a payload into a PVC Needle Complex, and related methods for manufacturing a packaged PVC Needle Complex. The payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof, and the leader sequence and the payload form an effector fusion that is distinct from a wild-type PVC effector protein.SELECTED DRAWING: Figure 3B

The purpose of the present invention is to provide a nucleic acid molecule, a vector, recombinant cells, and a drug for treating a central nervous system disease which is likely to migrate into the central nervous system. The nucleic acid molecule according to the present invention comprises a base sequence encoding a fusion protein of: an anti-transferrin receptor (TfR) antibody or an antigen-binding fragment thereof; and a protein which functions in the central nervous system.

This invention provides an HBV vaccine and a method for treating HBV. [Solution] A polypeptide useful for inducing a protective immune response to one or more hepatitis B virus (HBV) antigens in humans is provided. The immunogenic polypeptides described herein can induce prophylactic and / or therapeutic immune responses in humans to one or more hepatitis B virus (HBV) antigens. Generally, the immunogenic polypeptides described herein contain highly conserved portions of the HBV protein to induce a response to epitopes that are identical in vaccine antigens and in infectious HBV present in patients, while excluding poorly conserved regions, thereby avoiding the induction of an immune-dominant T cell response targeting epitopes that are not present in the patient's infectious HBV strain.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

This invention provides pharmaceutical compositions for inhibiting inflammation and their applications. The invention reveals that the combined use of hyaluronic acid synthesis inhibitors and ascorbate palmitate or their analogues can synergistically inhibit inflammation, significantly improving the therapeutic effect; the inflammation may include systemic inflammation and SARS-CoV-2 infection-related inflammation, including pneumonia. This invention also reveals a novel coronavirus inflammation model obtained by stimulating cells with specially isolated polynucleotides derived from the novel coronavirus genome. The model exhibits a typical inflammatory phenotype, is stable and controllable, and is intuitive and easy to observe.

The present invention provides artificial nucleic acid molecules comprising novel combinations of 5' and 3' untranslated region (UTR) elements. The nucleic acid molecules of the present invention are preferably characterized by increased expression efficiency of the coding region operably linked to the UTR elements. The artificial nucleic acids can be used to treat or prevent various diseases. The present invention further provides (pharmaceutical) compositions, vaccines, and kits comprising the artificial nucleic acid molecules. Furthermore, an in vitro method for preparing the artificial nucleic acid molecules of the present invention is provided.

A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

The present invention provides a device and method for delivering an effective amount of therapeutic agent, such as a vaccine, to a target that needs it. [Solution] Microneedles and microneedle devices, kits, and methods for manufacturing and using them, including implantable tips (e.g., silk-based tips) for sustained skin delivery of coronavirus and / or influenza vaccines, are described herein. In other embodiments, compositions and methods for controlled or sustained administration of coronavirus and / or influenza vaccines are also described for providing improved immunogenicity and / or broad-spectrum immunity.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The present disclosure provides engineered T cell receptors (TCRs), cells that contain TCRs, and methods for making and using TCRs. The present disclosure relates to TCRs that specifically recognize epitopes derived from tumor antigen NDC80 CT. Thus, aspects of the present disclosure relate to engineered T cell receptors (TCRs), nucleic acids that code TCRs, and cells that contain the nucleic acids and TCRs. Also provided are compositions that include the cells, nucleic acids, or engineered TCRs of the present disclosure, methods for making the cells, and methods for using aspects of the present disclosure for therapeutic treatment. TIFF2024538169000023.tif71128

Providing nucleic acid molecules and other components for targeting the CYP4V2 gene. [Solution] This disclosure provides nucleic acid molecules (e.g., sgRNA or gRNA molecules) for targeting the CYP4V2 gene encoding the cytochrome P450, family 4, subfamily V, polypeptide 2 protein, and donor nucleic acid molecules specific to the CYP4V2 gene. The use of these for targeting, disrupting and / or modifying mutations (e.g., c.802-8_810del17insGC mutation) of the human CYP4V2 gene, and for the treatment of crystallin retinopathy (BCD), is also provided.

To provide separation moieties, and methods of use thereof.SOLUTION: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions. Provided herein are compositions and methods to generate and use high efficiency separation moieties and / or linkers. The linkers can confer site-selectivity with regards to biological activity of the attached payload or payloads. In some embodiments, the separation moieties and / or linkers are used in conjugation with therapeutic proteins to treat a disease or disorder, such as proliferative disease, a tumorous disease, an inflammatory disease, an immunological disease, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, and a graft-versus-host disease.SELECTED DRAWING: None

The present invention generally relates to radiolabeled, preferably fluorescently labeled radiopharmaceuticals, and their use as tracers, imaging agents in nuclear medicine, and for the treatment of various disease states of PSMA-expressing cancer, particularly prostate cancer, and its metastases, as well as their use in preoperative PET imaging and fluorescence-guided surgery of cancer, particularly prostate cancer, and its metastases.

To provide products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies.SOLUTION: In methods, a protein including a linker domain, such as the heparin-binding domain of Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HBEGF), is delivered to patients. Provided herein are methods and products for treatment of CMDs such as dystroglycanopathies and laminin-deficient muscular dystrophies. The products include therapeutic proteins and rAAV encoding disclosed therapeutic proteins.SELECTED DRAWING: None

The present invention provides a composition comprising non-immunomodulatory, engineered, plant-derived extracellular vesicles (EVs) for use as a vaccine, said vesicles being loaded with an exogenous nucleic acid molecule encoding a protein antigen, and a method for preparing said composition, said method using one or more polycationic substances and one or more sugar molecules.

To provide chimeric antigen receptors, T cells expressing the chimeric antigen receptors, and methods of using the chimeric antigen receptors for prevention and / or treatment of cancer.SOLUTION: A chimeric antigen receptor comprises an antigen-recognition domain and a signalling domain, wherein the antigen-recognition domain recognizes a dysfunctional P2X7 receptor.SELECTED DRAWING: Figure 1

This invention provides single-stranded variable fragments (scFVs) specific to mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. [Solution] An isolated molecule comprising an antibody variable region that specifically binds to a complex of an HLA molecule and a peptide which is part of a protein, wherein the peptide contains a mutant residue, and the mutant residue is located within an intracellular epitope of the protein, the molecule does not specifically bind to the HLA molecule when the HLA molecule is not in the complex, and the molecule does not specifically bind to the peptide in its wild-type form.

Provided is a truncated TRIM72 protein comprising a coiled PRYSPRY domain or a PRYSPRY domain of the TRIM72 protein, or a functional fragment thereof. Also provided is the use of the truncated TRIM72 protein.

The present invention provides methods and materials for treating mammals (e.g., humans) that have or are at risk of developing a disease or condition characterized by tissue inflammation and / or degeneration. [Solution] For example, mesenchymal stem cells (MSCs) that express tissue-targeting antigen receptors (e.g., chimeric antigen receptors) capable of exerting immunosuppressive effects in targeted tissues are provided, as well as a method using such MSCs.

To further improve clinical outcomes, this provides a novel target for adoptive T-cell therapy approaches. [Solution] A T cell receptor (TCR) and a TCR variable region are provided that can selectively bind to the Hormad1 peptide / MHC complex. The TCR can be used in a variety of therapies, such as autologous Hormad1-TCR adoptive T cell therapy for treating cancers such as solid tumors that express Hormad1. A method for expanding and proliferating the associated T cell population is provided.